Rankings / Sleep & Recovery

Pentosan polysulfate (Elmiron)

Sleep & Recovery · Semisynthetic heparinoid

Tier C

Reviewed by Read Off Label · Last reviewed · How we grade

prescription
4.8 / 10
Tier C
Ev 4.5 Bn 5 Sf 5

Bottom line

Read Off Label grades Pentosan polysulfate (Elmiron) as C (4.8/10) based on weak-moderate evidence, med benefit magnitude, and a med-risk safety profile.

Elmiron received a 2020 FDA label update for pigmentary maculopathy risk — major class-action litigation followed.

Studied, labeled, or reported-use context: 100 mg PO 3x/day (Elmiron); 3 mg/kg IM weekly x4 (veterinary adaptation) — Rx (Elmiron — interstitial cystitis); off-label injectable (veterinary zydax) used by some humans; not individualized guidance.

What the evidence says

Elmiron received a 2020 FDA label update for pigmentary maculopathy risk — major class-action litigation followed. 'PPS injections' are a fringe human biohacker use of the veterinary formulation for joints, outside of any approved indication. A 2026 21-year FAERS pharmacovigilance analysis (68% of reports serious) reaffirmed maculopathy as the dominant signal and additionally flagged a not-yet-labeled psychiatric adverse-event signal.

Mechanism

Semisynthetic sulfated xylan polysaccharide; weak anticoagulant; reported DMOAD-like (disease-modifying) effects on osteoarthritis via cartilage matrix support and reduced proteolytic damage

Studied, labeled, or reported dose & route

100 mg PO 3x/day (Elmiron); 3 mg/kg IM weekly x4 (veterinary adaptation)

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Pentosan polysulfate (Elmiron)'s effects?
Read Off Label rates the evidence for Pentosan polysulfate (Elmiron) as Weak-Moderate and the benefit magnitude as med, producing an overall grade of C (4.8/10). Elmiron received a 2020 FDA label update for pigmentary maculopathy risk — major class-action litigation followed.
What safety findings are reported for Pentosan polysulfate (Elmiron)?
Pentosan polysulfate (Elmiron) has a med risk profile in the database. Med (pigmentary maculopathy with long-term Elmiron use — FDA warning 2020; bleeding risk; vet indication has fewer reported ocular issues) Legal status: Rx (Elmiron — interstitial cystitis); off-label injectable (veterinary zydax) used by some humans.
What doses or routes are reported for Pentosan polysulfate (Elmiron)?
100 mg PO 3x/day (Elmiron); 3 mg/kg IM weekly x4 (veterinary adaptation) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Pentosan polysulfate (Elmiron) work?
Semisynthetic sulfated xylan polysaccharide; weak anticoagulant; reported DMOAD-like (disease-modifying) effects on osteoarthritis via cartilage matrix support and reduced proteolytic damage

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.